Literature DB >> 12084281

Recent progress in the biology and treatment of Wilms' tumor.

M L Ritchey1.   

Abstract

The survival rate of patients with Wilms' tumor has rapidly improved in the last few decades. As we enter into the new millennium, overall survival for all Wilms' tumor patients exceeds 80%. Two large cooperative groups prospectively studied children with nephroblastoma: the National Wilms' Tumor Study Group, and the International Society of Paediatric Oncology. This review details the recent progress in understanding the biology of Wilms' tumor. Advances in clinical management of children with nephroblastoma are also outlined.

Entities:  

Mesh：

Year:  2001        PMID： 12084281     DOI： 10.1007/s11934-001-0009-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


  32 in total

1.  Renal findings on radiological followup of patients with Beckwith-Wiedemann syndrome.

Authors:  J G Borer; M Kaefer; C E Barnewolt; E R Elias; N Hobbs; A B Retik; C A Peters
Journal:  J Urol       Date:  1999-01       Impact factor: 7.450

2.  Rarity of surgical complications after postchemotherapy nephrectomy for nephroblastoma. Experience of the International Society of Paediatric Oncology-Trial and Study "SIOP-9". International Society of Paediatric Oncology Nephroblastoma Trial and Study Committee.

Authors:  J Godzinski; M F Tournade; J deKraker; J Lemerle; P A Voute; A Weirich; R Ludwig; M Rapala; G Skotnicka; F Gauthier; C G Moorman-Voestermans; D Buerger; A VanVeen; K Sawicz-Birkowska
Journal:  Eur J Pediatr Surg       Date:  1998-04       Impact factor: 2.191

3.  Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor.

Authors:  D H Rowe; J Huang; M L Kayton; R Thompson; A Troxel; K M O'Toole; D Yamashiro; C J Stolar; J J Kandel
Journal:  J Pediatr Surg       Date:  2000-01       Impact factor: 2.545

4.  Metastasis correlates with production of vascular endothelial growth factor in a murine model of human Wilms' tumor.

Authors:  M L Kayton; D H Rowe; K M O'Toole; R B Thompson; M A Schwarz; C J Stolar; J J Kandel
Journal:  J Pediatr Surg       Date:  1999-05       Impact factor: 2.545

5.  Is partial nephrectomy appropriate treatment for unilateral Wilms' tumor?

Authors:  C G Moorman-Voestermans; D C Aronson; C R Staalman; J F Delemarre; J de Kraker
Journal:  J Pediatr Surg       Date:  1998-02       Impact factor: 2.545

6.  Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.

Authors:  D M Green; N E Breslow; J B Beckwith; J Z Finklestein; P E Grundy; P R Thomas; T Kim; S J Shochat; G M Haase; M L Ritchey; P P Kelalis; G J D'Angio
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

Review 7.  Extensively cystic renal neoplasms: cystic nephroma, cystic partially differentiated nephroblastoma, multilocular cystic renal cell carcinoma, and cystic hamartoma of renal pelvis.

Authors:  J N Eble; S M Bonsib
Journal:  Semin Diagn Pathol       Date:  1998-02       Impact factor: 3.464

8.  Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group.

Authors:  M L Ritchey; D M Green; P R Thomas; G R Smith; G Haase; S Shochat; J Moksness; N E Breslow
Journal:  Med Pediatr Oncol       Date:  1996-02

9.  Constitutional WT1 mutations in Wilms' tumor patients.

Authors:  L Diller; M Ghahremani; J Morgan; P Grundy; C Reeves; N Breslow; D Green; D Neuberg; J Pelletier; F P Li
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

10.  Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour.

Authors:  R G Grundy; J Pritchard; P Scambler; J K Cowell
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.